Ricerca e articoli accademici sul preparato ImunoBran MGN-3
Arabinoxylan Rice Bran (MGN-3) Enhances the Effects of Interventional Therapies for the Treatment of Hepatocellular Carcinoma: A Three-year Randomized Clinical Trial PEER REVIEWED
Mai Hong Bang, Tran Van Piep, Nguyen Tien Thinh, Le Huu Song, Trinh Tuan Dung, Le Van Truong, Le Van Don, Thai Doan Ky, Deyu Pan, Magda Shaheen and Mamdooh Ghoneum
(edited by Chris Gutch PhD.)
Background and Aims: This study examined the efficacy of arabinoxylan rice bran (MGN-3) in conjunction with an interventional therapy (IT) for the treatment of hepatocellular carcinoma patients. Patients and Methods: A total of sixty-eight patients with hepatocellular carcinoma (stages I and II) participated in the study. Patients were randomized to receive IT (30 patients, control group) or IT+MGN-3 (38 patients), and randomly divided into two groups using a computer-generated randomization list. Patients and investigators were blinded. IT included transarterial oily chernoembolization (TOCE) or a combination of TOCE and percutaneous ethanol injection treatment (PEIT). Results: Patients in the IT+MGN-3 group showed: (i) lower recurrence ofthe disease, 3l.6% (I2/38), as compared to 46.7% (I4/30) for the control; (ii) higher survival aher the second year, 35%, as compared to 6.7% for the control; (iii) significantly lower alpha-fetoprotein level, a 38% decrease (p=0,()001), as compared to baseline value, while the control showed no signficant change; and (iv) a significant decrease in tumor volume, in contrast to the control, which showed no significant change. When the results were analyzed according to each IT modality, MGN-3+IT sub-groups displayed a greater response to treatment, in every aspect examined, than the IT sub-groups alone, Howeven the patients in the MGN-3+TOCE+PEIT sub-group demonstrated greater reduction in AFP levels and longer survival time than the MGN-3+TOCE; sub-group. Conclusion: MGN-3 in conjunction with IT may be usefull at the treatment of hepatocellular carcinoma and warrants farther investigation in multiple clinical trials.